3.890USD-0.51%Mkt Cap: 307.03M USDP/E: —Last update: 2026-06-01
Prelude Therapeutics Incorporated, a clinical-stage precision oncology company, focuses on the discovery and development of novel precision cancer medicines to underserved patients. It is developing JAK2V617F, a driver m…
Industry Peers
Biotechnology111.39BUSDP/E 26.0
100.62BDKKP/E 19.4
62.97BUSDP/E 14.7
48.39BEURP/E 31.7
44.65BEURP/E 37.2
40.10BUSDP/E 75.3
35.22BUSD—
32.91BSEKP/E 48.6
Indicators:|
Key Statistics
Company
Market Cap307.03M USD
Enterprise Value247.58M USD
Revenue (TTM)16.72M USD
Gross Profit16.72M USD
Net Income (TTM)-99.50M USD
Revenue/Share0.2130 USD
Last Price3.890 USD
Fiscal Year EndDec 2025
MR QuarterMar 2026
Employees79
CountryUS
SectorHealthcare
IndustryBiotechnology
ISIN—
Valuation
P/E (Trailing)—
P/E (Forward)-4.17
PEG—
EV/EBITDA-3.05
EV/Revenue14.81
P/S18.67
P/B4.10
EPS (TTM)-1.00
EPS (Forward)-0.94
52W Range
0.750066% of range5.540
52W High5.540 USD
52W Low0.7500 USD
Profitability
Gross Margin100.00%
Oper. Margin-309.54%
EBITDA Margin0.00%
Profit Margin-819.59%
ROE-144.96%
ROA-70.41%
Growth
Revenue Growth—
Earnings Growth—
Cash Flow & Leverage
Operating CF-56.30M USD
CapEx (TTM)67.00K USD
FCF Margin-107.24%
FCF Yield-5.84%
Net Debt-63.83M USD
Net Debt/EBITDA0.79
Balance Sheet
Debt/Equity0.26
Current Ratio2.03
Quick Ratio1.96
Book Value/Sh0.9550 USD
Cash/Share1.024 USD
Dividends
Fwd Div Rate—
Trail. Div Rate0.0000 USD
Div. Yield—
5Y Avg Yield—
Payout Ratio0.00%
Ex-Div Date—
Pay Date—
Analyst Consensus
Rating1.3 (Strong Buy)
Target (Mean)8.000 USD
Target Range6.000 USD – 10.00 USD
# Analysts3
Ownership
Shares Out.64.92M
Float22.96M
Insiders13.80%
Institutions64.32%
Short Interest
Short Ratio3.2d
Short % Float7.36%
Short % Out.2.32%
Shares Short1.85M
Short (prev mo.)1.81M
Technical
SMA 504.202 (-7.4%)
SMA 2002.443 (+59.3%)
Beta1.10
S&P 52W Chg27.70%
Avg Vol (30d)462.64K
Avg Vol (10d)333.17K
Technical Indicators
RSI (14)40.1
MACD-0.0785
MACD Signal0.0255
MACD Hist.-0.1040
BB Upper5.139 USD
BB Middle4.496 USD
BB Lower3.852 USD
BB Width28.62%
ATR (14)0.4309 USD
Vol Ratio (20d)0.53x